Fatal immune hemolytic anemia due to cefotetan

G. Garratty, S. Nance, M. Lloyd, R. Domen

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


In the first death associated with immune hemolytic anemia due to cefotetan, the patient developed hemolytic anemia and renal failure, dying 12 days after the beginning of 1 week's cefotetan therapy. The patient's serum contained strong antibodies reacting with cefotetan‐ treated red cells (RBCs) and with uncoated RBCs in the presence of cefotetan; a much weaker, drug‐independent antibody was also detected. Three‐days before the patient's death, the antibody reacting with cefotetan‐coated RBCs rose to a titer of 262,144; the titer of the antibody to uncoated RBCs, in the presence of cefotetan, rose to 2048; the titer of the drug‐independent antibody remained at 4. 1992 AABB

Original languageEnglish (US)
Pages (from-to)269-271
Number of pages3
Issue number3
StatePublished - 1992

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Hematology


Dive into the research topics of 'Fatal immune hemolytic anemia due to cefotetan'. Together they form a unique fingerprint.

Cite this